ARA-290 vs Boswellia (AKBA)
A side-by-side research comparison of ARA-290 and Boswellia (AKBA) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | ARA-290 | Boswellia (AKBA) |
|---|---|---|
| Full name | Cibinetide (ARA-290) | Boswellia Serrata Extract (AKBA) |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | Investigational | OTC supplement |
| Mechanism | Selectively activates the innate repair receptor (a heteromer of the EPO receptor and the beta-common receptor), triggering anti-inflammatory and tissue-protective signaling while avoiding hematopoietic stimulation. | AKBA (acetyl-11-keto-beta-boswellic acid) selectively inhibits 5-lipoxygenase (5-LOX), reducing pro-inflammatory leukotrienes. This targets a different inflammatory pathway than NSAIDs (which act on COX), sparing the stomach lining. |
| Molecular weight | ~1257 Da | 512.7 Da (AKBA) |
| Half-life | Short (minutes in plasma); effects outlast plasma levels | ~6 hours (AKBA) |
| Bioavailability | High via subcutaneous injection | Low; improved by AKBA-standardized and phytosome forms |
| Typical dose | 1-4 mg per dose | 100-250 mg AKBA-standardized, 1-2x daily |
| Frequency | Daily during a course | 1-2x daily |
| Route | Subcutaneous injection | Oral capsule |
ARA-290 reported benefits
- Reduces neuropathic pain
- Anti-inflammatory tissue protection
- Supports small-fiber nerve repair
- No increase in red blood cell mass (unlike EPO)
Boswellia (AKBA) reported benefits
- Reduces joint pain and stiffness
- Non-NSAID (stomach-sparing) anti-inflammatory
- Supports gut inflammation (IBD research)
- Cartilage protection
- Anti-inflammatory via 5-LOX inhibition
Related comparisons
Research and educational reference only. Not medical advice.